← All Sponsors
SPONSOR

Nurix Therapeutics, Inc.

Total Trials
1
Recruiting
1
Phases
Phase 2
Conditions studied: Chronic Lymphocytic Leukemia (CLL)Small Lymphocytic Lymphoma (SLL)
NCT07221500 Phase 2
Recruiting

A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)

Chronic Lymphocytic Leukemia (CLL)
United States, France, Italy View Trial →